Gelteq Partners with IDT Australia for New Product Development and Manufacturing Facilities

Strategic Partnership Between Gelteq and IDT Australia

Gelteq Limited, a clinical and science-based company focused on developing and commercializing white label ingestible gel-based solutions for prescription drugs, nutraceuticals, pet care, sports, and other products, has recently announced a significant partnership. The company has entered into a memorandum of understanding with IDT Australia (ASX: IDT), aiming to establish a dedicated, locally based manufacturing facility. This initiative is designed to support the development and scale-up of Gelteq’s gel-based products across diverse global markets, including pharmaceutical, nutraceutical, and animal health sectors.

IDT Australia is well-known for its extensive experience in pharmaceutical projects and contract manufacturing services. With over 50 years of operation and more than 60 market-based drugs, the company specializes in pharmaceutical product development and cGMP manufacturing. This includes high containment and high potency manufacture of Active Pharmaceutical Ingredients (API), oral and sterile dose FDA and TGA approved laboratory testing, and clinical packaging. Additionally, IDT is at the forefront of developing and manufacturing advanced therapies such as mRNA and Antibody Drug Conjugates (ADCs).

Benefits of the Partnership

The collaboration between Gelteq and IDT is expected to bring several advantages. Nathan Givoni, CEO of Gelteq, emphasized that partnering with IDT will strategically position the company to accelerate and scale its products for the global nutraceutical, pharmaceutical, and animal health markets. He noted that IDT brings proven development, manufacturing, and regulatory expertise, along with a unique knowledge base to speed up the development of new products targeting these markets.

Paul McDonald, CEO of IDT Australia, expressed excitement about combining IDT’s proven development and manufacturing capabilities with Gelteq’s innovative delivery system for wellness and therapeutic products. He highlighted that Gelteq’s proprietary gel technologies offer distinct benefits in both delivery and combination therapy opportunities needed to improve care and dosing compliance across many end markets.

Key Highlights of the Agreement

The agreement outlines several key components:

• Facilities and Equipment: The agreement includes the facilities and equipment required for the manufacture of Gelteq products in a dedicated building and purpose-built facility, along with trained staff and operational support.
• Compliance and Certification: It covers the necessary compliance and certification for products in the therapeutic, veterinary, and nutraceutical markets across various product presentations. This includes regulatory requirements, permits, and licenses from the APVMA, FDA, and TGA.
• Rapid Scale-Up Capability: The agreement also provides for the integration of additional manufacturing space and equipment to support growth.

About Gelteq Ltd.

Based in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, sports, and other products. The company advances and commercializes its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition.

Gelteq's unique formulation addresses issues associated with traditional drug delivery methods, such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit www.gelteq.com and the SportsGel brand website at www.sportsgel.com.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and are subject to inherent uncertainties, risks, and assumptions. Risks include the timing and fulfillment of current and future orders, the success of new programs, and the ability to implement and succeed with a new strategic plan. For a detailed discussion of risks and uncertainties, refer to the risk factors in Gelteq's Annual Report on Form 20-F filed on November 15, 2024. All forward-looking statements speak only as of the date they are made, and Gelteq undertakes no obligation to update or revise them.